GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entheon Biomedical Corp (XCNQ:ENBI) » Definitions » Retained Earnings

Entheon Biomedical (XCNQ:ENBI) Retained Earnings : C$-21.38 Mil (As of Feb. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entheon Biomedical Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Entheon Biomedical's retained earnings for the quarter that ended in Feb. 2024 was C$-21.38 Mil.

Entheon Biomedical's quarterly retained earnings declined from Aug. 2023 (C$-20.63 Mil) to Nov. 2023 (C$-21.31 Mil) and declined from Nov. 2023 (C$-21.31 Mil) to Feb. 2024 (C$-21.38 Mil).

Entheon Biomedical's annual retained earnings declined from Nov. 2021 (C$-13.55 Mil) to Nov. 2022 (C$-21.61 Mil) but then increased from Nov. 2022 (C$-21.61 Mil) to Nov. 2023 (C$-21.31 Mil).


Entheon Biomedical Retained Earnings Historical Data

The historical data trend for Entheon Biomedical's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entheon Biomedical Retained Earnings Chart

Entheon Biomedical Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Nov21 Nov22 Nov23
Retained Earnings
Get a 7-Day Free Trial -0.72 -0.87 -13.55 -21.61 -21.31

Entheon Biomedical Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Feb21 May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -20.68 -20.53 -20.63 -21.31 -21.38

Entheon Biomedical Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.


Entheon Biomedical  (XCNQ:ENBI) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.


Entheon Biomedical (XCNQ:ENBI) Business Description

Traded in Other Exchanges
Address
999 West Broadway Street, Suite 720, Vancouver, BC, CAN, V5Z 1K5
Entheon Biomedical Corp is a biotechnology research and development company committed to developing and commercializing a portfolio of safe and effective Dimethyltryptamine based psychedelic therapeutic products (DMT Products) for the purposes of treating addiction and substance use disorders. Entheon intends to generate revenue through the sale of its DMT Products to physicians, clinics, and licensed psychiatrists in the United States, certain countries in the European Union, and throughout Canada.
Executives
Brian Jahns Senior Officer

Entheon Biomedical (XCNQ:ENBI) Headlines

No Headlines